About this journal

Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization.

Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community.

Regenerative Medicine exclusively supports all avenues that lead to the replacement or regeneration of human cells, tissue or organs, to restore or establish normal function. The sector is complex, rapidly evolving and multidisciplinary in nature, however, Regenerative Medicine is highly dynamic and has always embraced the progress made by the field and moved accordingly to support the critical issues including:

• Bench-to-bedside translation
• Tissue engineering and organ replacement
• Regenerative pharmacology
• Cell and gene therapy
• Regenerative nanotechnology
• Manufacturing and cost of goods
• Regulatory and reimbursement
• Ethical and legal perspectives
• Business models and commercialization
• Government policy

Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.

Senior Editors

Chris Mason, Professor of Cell & Gene Therapy, Advanced Centre for Biochemical Engineering, University College London, UK; and Chief Science Officer, AVROBIO, MA, USA
Andre Terzic, Director, Center for Regenerative Medicine, Mayo Clinic, MN, USA

Associate Editors

Robert Lanza, Astellas Global Regenerative Medicine, CA, USA
Phillipe Menasché, Hôpital Européen Georges Pompidou, FR
Gail K Naughton, Histogen Inc., CA, USA
Glyn Stacey, SSCBio Ltd, UK

Editorial Board

Robin Ali, King's College London, UK
Tim Allsopp, Consilium Bio Ltd, UK
Anthony Atala, Wake Forest University School of Medicine, US
Roger Barker, Cambridge Centre for Brain Repair, UK
Steven Bauer, FDA/Center for Biologics Evaluation and Research, US
Nissim Benvenisty, Hebrew University of Jerusalem, IS
Oliver Brüstle, Bonn University, DE
Lee Buckler, Blood Centers of America, RI
Timothy Caulfield, University of Alberta, CA
Julian Chaudhuri, University of Bath, UK
Steve Dalton, University of Georgia, GA, US
Fayad Dandashi, Ministry of Health, SA
Cosimo De Bari, University of Aberdeen, UK
Daniel Garry, University of Minnesota, MN, US
Karen Hirschi, Yale University, CT, US
Dusko Ilic, King’s College London, UK
Silviu Itescu, Mesoblast, AU
Christian Jorgensen, INSERM, FR
Ben Kaplan, Ben’s Stem Cell News, US
Hans Keirstead, AIVITA Biomedical Inc., CA, US
Paul Kemp, Intercytex, UK
Robert Kloner, Keck School of Med. (USC), CA, US
Paul Knoepfler, University of California Davis, CA, US
Vassilis Koliatsos, Johns Hopkins University School of Medicine, MA, US
Majlinda Lako, University of Newcastle, UK
Cato Laurencin, University of Connecticut, CT, US
James Lawford Davies, Hill Dickinson, UK
Jane Lebkowski, Asterias Biotherapeutics, CA, US
Nico L'Heureux, INSERM, FR
Ren- Ke Li, University of Toronto, ON, CA
Geoff Mackay, AVROBIO Inc., MA, US
Paolo Madeddu, University of Bristol, UK
Gianvito Martino, San Raffaele Hospital, Milan, Italy
Robert Miller, George Washington University, Washington, D.C, US
Norio Nakatsuji, Kyoto University, JP
Richard Oreffo, University of Southampton, UK
Amit Patel, McGowan Institute for Regenerative Medicine, PA, US
Marc Penn, Summa Health System, OH, US
Mahendra Rao, Pluristyx Inc, WA, US
Jon Rowley, RoosterBio, MD, US
Alan Russell, Carnegie Mellon University, PA, US
Eleftherios (Terry) Sachlos, Bikanta, CA, US
Brian Salter, King’s College London, UK
Paul Sanberg, USF College of Medicine, FL, US
Raphael Scharfmann, INSERM, FR
Paul Sharpe, King’s College, London, UK
Bernie Siegel, Regenerative Medicine Foundation, FL, US
Doug Sipp, RIKEN, JP
Evan Snyder, The Burnham Institute, US
Mark Sussman, SDSU Heart Institute, CA, US
Alain Vertès, NxR Biotechnologies GmbH, CH
Scott Waldman, Thomas Jefferson University, PA, US
Young-Sup Yoon, Emory University School of Medicine, GA, US
Lorraine Young, University of Nottingham, UK